AYTU BIOPHARMA, INC Finance Lease, Right-of-Use Asset, Amortization
AYTU BIOPHARMA, INC (AYTU) reported Finance Lease, Right-of-Use Asset, Amortization of $14.00 thousand for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:FinanceLeaseRightOfUseAssetAmortization · last filed 2023-11-14
- AYTU BIOPHARMA, INC finance lease, right-of-use asset, amortization for the quarter ending 2023-09-30 was $14.00K, a 22.22% decline year-over-year.
- AYTU BIOPHARMA, INC finance lease, right-of-use asset, amortization for the quarter ending 2023-06-30 was $15.00K, a 16.67% decline year-over-year.
- AYTU BIOPHARMA, INC finance lease, right-of-use asset, amortization for the quarter ending 2023-03-31 was $14.00K, a 22.22% decline year-over-year.
- AYTU BIOPHARMA, INC finance lease, right-of-use asset, amortization for the quarter ending 2022-12-31 was $19.00K, a 0.00% change year-over-year.
- AYTU BIOPHARMA, INC finance lease, right-of-use asset, amortization for fiscal 2023 was $66.00K, a 9.59% decline from fiscal 2022.
- AYTU BIOPHARMA, INC finance lease, right-of-use asset, amortization for fiscal 2022 was $73.00K, a 247.62% increase from fiscal 2021.
- AYTU BIOPHARMA, INC finance lease, right-of-use asset, amortization for fiscal 2021 was $21.00K.
| Period end | Finance Lease, Right-of-Use Asset, Amortization 3 month | Finance Lease, Right-of-Use Asset, Amortization 6 month | Finance Lease, Right-of-Use Asset, Amortization 9 month | Finance Lease, Right-of-Use Asset, Amortization 12 month |
|---|---|---|---|---|
| 2023-09-30 | $14.00K 10-Q · filed 2023-11-14 | $29.00K derived: sum of 2 quarters · filed 2023-11-14 | $43.00K derived: sum of 3 quarters · filed 2023-11-14 | $62.00K derived: sum of 4 quarters · filed 2023-11-14 |
| 2023-06-30 | $15.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-10-12 | $29.00K derived: sum of 2 quarters · filed 2023-10-12 | $48.00K derived: sum of 3 quarters · filed 2023-10-12 | $66.00K 10-K · filed 2023-10-12 |
| 2023-03-31 | $14.00K 10-Q · filed 2023-05-11 | $33.00K derived: sum of 2 quarters · filed 2023-05-11 | $51.00K 10-Q · filed 2023-05-11 | $69.00K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-12-31 | $19.00K 10-Q · filed 2023-02-21 | $37.00K 10-Q · filed 2023-02-21 | $55.00K derived: sum of 3 quarters · filed 2023-11-14 | $73.00K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-09-30 | $18.00K 10-Q · filed 2023-11-14 | $36.00K derived: sum of 2 quarters · filed 2023-11-14 | $54.00K derived: sum of 3 quarters · filed 2023-11-14 | $73.00K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $18.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-10-12 | $36.00K derived: sum of 2 quarters · filed 2023-10-12 | $55.00K derived: sum of 3 quarters · filed 2023-10-12 | $73.00K 10-K · filed 2023-10-12 |
| 2022-03-31 | $18.00K 10-Q · filed 2023-05-11 | $37.00K derived: sum of 2 quarters · filed 2023-05-11 | $55.00K 10-Q · filed 2023-05-11 | $57.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $19.00K 10-Q · filed 2023-02-21 | $37.00K 10-Q · filed 2023-02-21 | $39.00K derived: sum of 3 quarters · filed 2023-02-21 | $58.00K derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-09-30 | $18.00K 10-Q/A · filed 2023-02-21 | $20.00K derived: sum of 2 quarters · filed 2023-02-21 | $39.00K derived: sum of 3 quarters · filed 2023-02-21 | |
| 2021-06-30 | $2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-27 | $21.00K derived: sum of 2 quarters · filed 2022-09-27 | $21.00K 10-K · filed 2022-09-27 | |
| 2021-03-31 | $19.00K 10-Q · filed 2022-05-16 | $19.00K 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |